Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Jea Yu

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

The advent of GLP-1 treatments has been a game changer in the medical sector for weight loss and chronic obesity. The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy) produced by Novo Nordisk A/S (NYSE: NVO) and tirzepatide (Mounjaro and Zepbound) produced by Eli Lilly and Co. (NYSE: LLY). The once-a-week injections are still in short supply despite costing over $1,000 a month. Eli Lilly’s Mounjaro sales surged over 114% YoY in its Q3 2024.

However, health insurers are becoming more reluctant about coverage, and people with anxiety over needle injections are still staying away. Among all the new therapies in studies, a novel approach to weight loss utilizing ultrasound is being developed by Novo Nordisk and GE HealthCare Technologies Inc. (NASDAQ: GEHC).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.